Advertisement

The Latest

Arcion Therapeutics, a Baltimore-based clinical stage biotechnology company, received notice of allowance for a U.S. patent for its high-strength gel formulation of topical lidocaine, called ARC-2022, for pain associated with post-herpetic neuralgia and shingles, according to a company news release.

Advertisement